康泰醫學(300869.SZ)擬斥100萬元設立秦皇島隆躍科技
格隆匯 3 月 5日丨康泰醫學(300869.SZ)公佈,公司擬使用自有資金,在秦皇島市經濟技術開發區投資100萬元設立全資子公司秦皇島隆躍科技有限公司(暫定名,以最終註冊為準),並授權公司管理層負責辦理此投資設立子公司的相關事宜。
根據公司發展戰略的需要,為完善公司供應鏈管理,降低原材料採購成本,提高關鍵零部件供給的及時性和質量的可控性,進一步增強公司主營業務的競爭能力,擬在當地設立全資子公司作為投資主體開展相關業務。
子公司的建成和投產,有助於提升公司綜合實力和核心競爭力,對公司未來的發展具有積極意義。本次投資短期內不會對公司的財務狀況和經營成果產生重大影響,不存在損害上市公司及股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.